Epidemiologic and experimental evidence suggests the effectiveness of androgen deprivation therapy (ADT) in prostate cancer (CaP) management. Although ADT has been increasingly used as mono-therapy in CaP, the survival benefit of ADT remains unclear. We examined the effectiveness of ADT in prolonging survival in a community-based cohort of 64 475 older men diagnosed with locoregional CaP, in 1992-1999 with last follow-up through December 2002, in 11 Surveillance Epidemiology and End Results (SEER) registries. The effect of ADT on survival was assessed using Kaplan-Meier's method, log-rank test and Cox proportional hazards. After adjustment for propensity to receive ADT, the ADT and non-ADT groups were significantly different in the distribution of covariates except for comorbidity score and SEER registries. The crude overall mortality was significantly higher in cases with ADT compared with cases that received no ADT, hazard ratio (HR ¼ 1.54; 95% CI ¼ 1.50-1.58). However, mortality was substantially reduced (1.04, 1.00-1.08) after adjusting for standard care, socio-demographics, tumor characteristics, prognostic factors and chemotherapy. Therefore, ADT was not associated with significantly increased survival benefit for older men with locoregional CaP. Further studies may be needed to explore whether ADT is associated with other health benefits and the cost-effectiveness of these benefits.
Introduction
Androgen deprivation therapy (ADT) has been a mainstay for managing advanced prostate cancer (CaP) since the first report of hormonal manipulation of prostate carcinoma cells over 60 years ago. 1, 2 Huggins and Hodges 1 demonstrated the reduction in androgen levels following bilateral orchiectomy, decreased progression of prostatic carcinoma and increased survival rates. The efficacy of ADT in CaP treatment is plausible since CaP is initially androgen-sensitive, thus, depending on androgens for growth and proliferation. 2, 3 Randomized Clinical Trials (RCTs) comparing maximum androgen blockade (MAB) with mono-therapy have indicated conflicting results in terms of survival benefits of ADT in CaP management. [4] [5] [6] Likewise, the efficacy of adjuvant hormonal therapy (HT) following surgery or radiation but not HT alone in CaP has been demonstrated in numerous RCTs with inconsistent results. [7] [8] [9] [10] [11] [12] [13] These studies showed a significant reduction in a 5-year follow-up for CaP-specific mortality, with survival benefit ranging from 37 to 81%. For example, a study observed a 59% decrease in cancer-specific mortality in patients with Gleason score of 8-10, 12 while another study, though not statistically significant, found a 39% reduction in CaP-specific mortality comparing luteinizing hormone-releasing hormone (LHRH) agonist plus radiation with radiation only regimen. 13 Specifically, the efficacy of a well-tolerated LHRH agonist in CaP treatment and their efficacy in prolonging life in localized CaP has been observed. 14, 15 A significant difference in prostate specific antigen (PSA) progression and organ-confined disease progression was shown in the Canadian trial of 3 and 8 months of leuprolide plus flutamide. 16 A highly significant overall survival benefit for external beam radiation therapy (ERBT) and ADT versus EBRT alone has also been reported. 10, 13, 17 The survival benefits in favor of radical prostatectomy plus HT versus radical prostatectomy alone have been equally demonstrated. 18, 19 In contrast, other clinical trials have shown that HT as adjuvant to primary standard care does not result in a clinically meaningful improvement in survival. [20] [21] [22] Further, a meta-analysis of 27 randomized trials with 8275 patients (88% with metastatic and 12% with locally advanced disease) comparing the survival benefit of MAB over androgen suppression monotherapy found 2-3% increased 5-year survival in favor of MAB. 23 However, since these studies had been conducted in controlled conditions, the efficiency of ADT in CaP management compared with other treatments in locoregional CaP remains to be fully assessed.
Randomized controlled trials are considered to be the gold standard in determining the efficacy of therapy. However, it is unknown whether efficacy under controlled conditions has been translated into the real-world effectiveness in routine practice. [24] [25] [26] [27] Given the increased use of HT in localized and metastatic CaP over the past many years, 28 and the increased cost, 29 it is imperative to assess the effectiveness of this therapy in prolonging survival for men treated for locoregional CaP in the routine community settings. To determine the effectiveness of ADT in a large community-based cohort of men diagnosed with locoregional CaP, we utilized a large community-based sample from Surveillance Epidemiology and End Results (SEER)-Medicare linked dataset of the National Cancer Institute (NCI). We hypothesized that ADT is effective in prolonging the overall survival in older men with locoregional CaP.
Materials and methods

Data source
After approval from the institutional review board at the University of Texas School of Public Heath, we conducted a retrospective cohort study using the merged SEER-Medicare database for men diagnosed with CaP at age 65 and older between 1992 and 1999 in the 11 SEER areas. SEER is a set of geographically defined, population-based, central cancer registries sponsored by the NCI. The source of data for this study was the database from the 11 SEER areas namely, metropolitan areas of San Francisco/Oakland, Detroit, Atlanta and Seattle; Los Angeles county, the San Jose-Monterey area; and the states of Connecticut, Iowa, New Mexico, Utah and Hawaii. These geographic areas represent an estimated 14% of the US population.
Study population. Patients with CaP diagnosed at age 65 years and older from 1992 to 1999 in the 11 SEER regions, who had both Medicare parts A and B and were not enrolled in any Health Maintenance Organization (HMO) at the time of diagnosis, were selected. We excluded men with metastatic disease. All races were included in the study population, namely Caucasians (n ¼ 53 764), African Americans (n ¼ 6321), Hispanics (n ¼ 1143), Asians (n ¼ 1830) and others (n ¼ 1417). Because SEER provides a combined category for CaP staging for regional and local tumor, the American Joint Committee on Cancer (AJCC) stage was used to control for residual confounding by the combined local/regional stages.
Study variables
Outcome variable. All-cause mortality was defined as death from any cause reported as the underlying cause of death. The survival time in months was calculated from the month of diagnosis to the month of death or to the day of last follow-up (December 31, 2002).
ADT (HT and orchiectomy). ADT was defined as either HT or orchiectomy. HT was described as the receipt of LHRH agonist. Patients were characterized as receiving androgen ablation or ADT if any of the following Medicare procedure codes indicated so within 6 months of diagnosis: procedure codes for leuprolide (J1950 or J9217-J9219) and for gorserelin (J9202) or procedure codes for orchiectomy (54520-5421, 54530 or 54535). Orchiectomy was defined as surgical castration for the purpose of suppressing testicular testosterone.
Chemotherapy, surgery and radiation. Patients were defined as having received chemotherapy if the Medicare procedures indicated so within 6 months of diagnosis. Chemotherapy was reported as either received or not received. The details of chemotherapy ascertainment have been described elsewhere. 30 The primary therapies in localized CaP include radical prostatectomy, radiotherapy or observational management. 31 Comorbidity. Comorbidity was ascertained from Medicare claims using diagnoses and procedures performed between 1 year before, and 1 month after CaP diagnosis. 32, 33 The comorbidity scores were categorized into four groups (0, 1, 2, 3 and higher). The details of the comorbidity ascertainment has been previously described. 32 Clinical features and other characteristics. The CaP data in this study represents locoregional (local/regional) stage. SEER defines localized disease as an invasive neoplasm confined entirely to organ of origin, while regional disease refers to a neoplasm that has extended beyond the limits of the organ of origin directly into surrounding organs or tissues. Both grade (Gleason score) and AJCC stages (I, II, III, IV or unknown) categories were used.
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Statistical analyses
Pearson w 2 statistic was used to assess differences in the distribution of explanatory prognostic, socio-demographic and treatment among those who received ADT and those who did not. The propensity score analysis was performed to adjust for differential distribution of prognostic factors between treated and untreated cases, since patients receiving treatment may differ from those not receiving by spectrum of prognostic factors. Propensity score is the probability that a patient would receive ADT. 35 The propensity score was divided into quintiles for all patients, which could remove over 90% of unbalanced bias from confounding factors between treated and untreated cases. 35 The Kaplan-Meier product limit was used to estimate the overall survival curve, adjusting for relevant covariates. In addition, the cumulative hazard function was estimated using Nelson-Aalen curves for ADT versus non-ADT groups. The log-rank test statistic was used to assess the equality of survival for ADT relative to non-ADT. This test is appropriate when the hazard rates are proportional to one another. 36 Assuming the hazard rate is proportional or constant and there are no timedependent covariates, Cox's proportional hazard regression model with the Breslow method for ties was used to assess the relative risk of dying in association with ADT, after adjusting for relevant covariates. Finally, the likelihood ratio test and extended Cox model were used to examine the fitness of the model and the proportional hazard assumption respectively, while Cox-Snell residual was used to assess the overall fit of the model. The probability values were two tailed at Po0.05 significance level. All analyses were performed using STATA statistical package, version 9.0. Table 1 presents the number and percentage of older men with locoregional CaP by various patient and cancer characteristics. The comparison of these factors between patients who received HT and those who did not, after adjusting for propensity score is presented as well. Though not shown on the table, those treated and untreated with ADT were statistically significantly different with respect to all covariates (w 2 ; Po0.05). Overall, 17 415 (27.0%) of men with locoregional CaP received ADT. A statistically significant difference in these covariates was observed between those treated and untreated with ADT (w 2 ; Po0.05). However, after adjustment for propensity score to receive ADT, there was no statistically significant difference in comorbidity and SEER geographic areas in cases treated and untreated with ADT (w 2 ; Po0.41) and (w 2 ; Po0.39), respectively. Table 2 presents the effect of ADT on all-cause mortality in men with locoregional CaP stratified by primary therapy, chemotherapy, age, Gleason score, tumor stage and comorbidity. After stratifying by radical prostatectomy (RP), radiation therapy (XRT), XRT plus RP and watchful waiting (WW), there was a statistically significant increase in all-cause mortality, 35, 56, 53 and 30%, respectively. The effect of ADT on mortality varied significantly across the primary therapy, indicating the confounding effect of primary therapy on the effect of ADT on overall survival of this cohort. Figure 1 also displays the unadjusted Kaplan-Meier's survival curve for the effect of ADT on survival in older men treated for locoregional CaP, with cases receiving ADT demonstrating survival disadvantage compared with the untreated cases. Table 3 presents the multivariable Cox proportional hazard model for the effect of ADT as well as other treatments on all-cause mortality. As illustrated in the final model (IV), among those who received ADT, there was a moderate but statistically marginal significant increased mortality compared with those who did not receive ADT. Model I adjusted for socio-demographic factors, comorbidity and tumor characteristics. Compared with cases not receiving ADT, those receiving ADT had 19% increased risk of dying (HR ¼ 1.19; 95% CI ¼ 1.15-1.22). Model II adjusted for primary therapy and chemotherapy (treatment model). Compared with cases not receiving ADT, ADT was statistically significantly associated with 29% increased risk of dying among cases that received ADT (HR ¼ 1.29; 95% CI ¼ 1.24-1.34). Model III adjusted for socio-demographics, tumor characteristics, comorbidity, primary therapy and chemotherapy. There was a statistically significant 4% increased mortality risk in those who received ADT compared with those who did not (HR ¼ 1.04; 95% CI ¼ 1.00-1.08). Model IV adjusted for all the covariates adjusted for in model III plus socioeconomic status (education, income and poverty). Collinearity was observed in the unknown education category, which was addressed by collapsing this category. There was no change in the risk of dying compared with the previous model, affirming a statistically marginally significant 4% increased risk of dying in those who received ADT compared with those who did not (HR ¼ 1.04, 95% CI ¼ 1.00-1.08). Figure 2 displays Kaplan-Meier absolute survival adjusted for all relevant covariates, with improved survival observed in both groups. Table 3 
Results
Discussion
Epidemiologic and experimental evidence about the survival benefit of adjuvant HT or ADT in men with CaP remains inconclusive. Some RCTs have shown the benefits of adjuvant HT used with primary curative intent (radical prostatectomy and radiotherapy) to provide survival benefits in some groups of patients with CaP 10-17,23,37 and others have shown no effect.
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Androgen Abbreviations: ADT, androgen deprivation therapy; AAs, African Americans; RP, radical prostatectomy; WW, watchful waiting or observational management. All pre-adjustment covariates were statistically significantly different at Po0.05. *P-value after adjustment for propensity score. First quartile refers to highest education and highest income levels.
a Both refer to participants receiving radical prostatectomy and radiation therapy while neither refers to patients on WW or observational management. b Comorbidity index/score, 0 means no concurrent disease conditions. *P-value after adjustment for propensity score, at o0.05 significance level.
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In this study, we have shown that ADT provided no survival benefit in older men with locoregional disease who received this treatment compared with those who did not. In fact, ADT was associated with a marginally decreased survival, after adjusting for propensity score and primary therapy, socio-demographic factors and tumor characteristics. This result in the communitybased setting supports some previous studies that showed that hormone therapy provided a palliative effect but did not prolong survival in patients with CaP.
20-22
The clinical model of CaP disease has been described. 38 This model indicates a progression from initial prostate evaluation, where prevention is the strategy given no diagnosed tumor, then clinically localized disease, where risk stratification is the strategy. The rising PSA is indicative of the strategy to prevent metastases. The failure of this strategy results in clinical metastases (noncastrate), and requires a strategy to delay tumor progression. Consequently, the progression to clinical metastasis (castrate) where death from other causes or cancer-specific death becomes most probable, involves a strategy to prolong survival and optimize the quality of life. 31 With this therapeutic objective, HT in CaP disease is not curative but palliative. 31, 38 The optimal benefits of HT may be illustrated in proper timing of therapy, tumor stage, age at diagnosis and risk stratification equation, 39 suggestive of efficacy as well as community-based effectiveness studies in younger populations.
An additional interesting finding in our study was the survival advantage of radical prostatectomy over XRT and WW. After adjustment for all clinically relevant and statistically significant covariates, cases receiving RP compared with those who underwent watchful waiting, RP was significantly associated with 68% decreased mortality risk (HR ¼ 0.32; 0.30-0.33), while those who received XRT compared with watchful waiting had a significant 37% decreased risk of dying. Our result, therefore, supports the role of radical prostatectomy in improving overall and prostate-cancer specific survival. [40] [41] [42] There are several strengths to the results obtained in this current study. Primarily, the data used in this study was obtained from the NCI's SEER program, which accounts for 14% of the total US population and ascertains nearly all cancer patients in the designated SEER registries. 43 The advantage of this sample is that the data include most older males residing in community-based settings, which deviates from selection bias often seen in randomized trials such as volunteer bias. In addition, because RCTs often have restricted enrollment criteria and are conducted in motivated volunteers, it is plausible to expect the effectiveness of ADT to be different in the community-based setting from the efficacy of ADT or HT observed in clinical trials.
This study is not without limitations. First, there is concern regarding the accuracy and completeness of information on HT and ADT from Medicare claims. However, it is unlikely that this study is flawed by the validation of the Medicare claims. Previous studies have affirmed the validation of chemotherapy from this data, 33, 34 which is similarly applicable to HT/ADT. Second, it is not possible to generalize the findings in Further, the results in this study are unlikely to be due to bias such as measurement error, selection bias or confounding effect of other covariates on the effect of ADT on all-cause mortality. Selection bias is a major issue in observational studies including this present study. Older men in our sample who received ADT were different in spectrum of prognostic indicators than those who did not. Men who received ADT were less likely to be younger, married, educated, have low Gleason score, receive RP, RP/XRT, and more likely to have comorbid conditions and undergo watchful waiting (observational management). These factors are either associated with tumor virulence or poor outcome. This selection bias may very well have influenced the result of our study. However, we minimized some of these biases by the propensity scores, stratified by the primary therapy and adjusted the hazard ratio for the effect of ADT on mortality by these sources of noncomparability (confoundings). Nonetheless, like in all epidemiologic studies, our results might still be influenced by unmeasured and residual confoundings.
This study also found that increase in overall mortality in this cohort was associated with advancing age, higher comorbidity score, higher Gleason score/AJCC stage, lower education and income, unmarried status and African American ethnic/racial group. These prognostic factors were significantly different between those who received HT and those who did not. These findings may be biased by differential distribution of these prognostic factors. While to some extent, this might be possible, it is however, unlikely that our finding of marginally significant increased risk of dying in those who received HT compared with those who did not was driven solely by this differential distribution of the prognostic factors, since we did minimize some of these imbalances by Androgen deprivation therapy and prostate cancer survival L Holmes Jr et al propensity scores, and adjusted for these confoundings in a multivariable Cox proportional hazard model using clinically relevant and statistically significant covariates. Likewise, there is a possibility of misclassification bias. SEER provided reliable information that was validated by SEER staff, and Medicare data have been both externally and internally validated by many researchers. 33, 43, 44 However, we cannot exclude the possibility of misclassification of the factors that may have resulted from modeling categorized variables that were originally continuous and measured with nondifferential error. 45 In summary, this study has shown that ADT was not associated with significantly increased survival benefit in older men with locoregional CaP living in the community. Therefore, given the possibilities of unmeasured and residual confoundings in this study, further studies may be needed to explore whether ADT is significantly associated with other health benefits, the cost-effectiveness of these benefits, and to determine whether or not similar results are obtainable in younger men and other populations of men with locoregional disease.
